A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis
This extension study of WA19926 will assess the long-term safety and the efficacy of
 RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis.
 Participants who have completed the core study WA19926 are eligible to participate.
 Participants will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The
 anticipated time on study drug is 104 weeks.
Inclusion Criteria:

 -  Adult participants, >/=18 years of age who have completed the core study WA19926 and
 according to the investigator may benefit from RoActemra/Actemra treatment

 -  No current or recent adverse event or laboratory finding preventing the use of the
 study drug dose at baseline

 -  Receiving treatment on an outpatient basis

 Exclusion Criteria:

 -  Females who are pregnant

 -  Participants who have prematurely withdrawn from the core study WA19926 for any reason

 -  Treatment with any investigational drug since the last administration of the study
 drug in the core study WA19926

 -  Treatment with an anti-tumor necrosis (TNF), anti-interleukin 1 agent or T-cell
 costimulation modulator since the last administration of the study drug in the core
 study WA19926

 -  Immunization with live/attenuated vaccine since the last administration of the study
 drug in the core study WA19926

 -  Diagnosis since the last WA19926 visit of rheumatic autoimmune disease or inflammatory
 joint disease other than rheumatoid arthritis

 -  Abnormal laboratory values